SANOFI diabete

Description Results NMA

single injection of glulisine before breakfast (n=-9)

vs.

single injection of glulisine before their main mealtime (breakfast, lunch or dinner); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

multiple daily injection using insulin lispro and insulin glargine (n=-9)

vs.

continuous subcutaneous insulin infusion using insulin lispro (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

bedtime glargine (n=-9)

vs.

NPH once daily (n=-9)

open-label

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

bedtime insulin glargine (n=-9)

vs.

bedtime NPH insulin (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

HbA1c <7% 2.56 [0.95; 6.86]

basal+bolus (single dose of insulin glulisine immediately prior to the main meal) (n=49)

vs.

basal insulin (glargin) (n=57)

open-label

Parallel groups

Sample size: 49/57

Primary endpoint:

FU duration: 3 months

AVE0010 (10,15 and 20 µg) in association with basal insulin, with or without metformin (n=328)

vs.

placebo on top basal insulin (n=167)

the type of basal insulin used during the trial is not specified in the available document

double-blind

Parallel groups

Sample size: 328/167

Primary endpoint: change from baseline in HbA1c

FU duration: 24 weeks